Drug Trial Radar · NCT02311231
Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART
Last checked: Nov 20, 2026Latest source record: May 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,012
Actual
Start
Jun 2014
Primary completion
Mar 2017
Study completion Mar 2017
Sponsor
- Lead sponsor
- Uppsala UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Lund University
- First posted
- Dec 8, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this trial we test the hypothesis that PCI and bivalirudin is superior to heparin alone (according to local protocol) in reducing death, MI, and major bleeding in patients with NSTEMI or STEMI at 180 days (primary end point), treated with ticagrelor or prasugrel.
Conditions
- ST-segment Elevation Myocardial Infarction
- Non ST-segment Elevation Myocardial Infarction
Interventions
bivalirudinDrug
Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
HeparinDrug
Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
Primary outcomes
What the sponsor says the trial is designed to measure.
- Death, Myocardial infarction and major bleeding eventTime frame: 180 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lund University
Lund, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.